Ara 290 Overview, Dosing & Safety | Peptide Database

Ara 290 (Cibinetide)

Tissue-Protective Peptide | Innate Repair Receptor Agonist

Community Research

Join others researching Ara 290 — share findings, ask questions, and learn from real experiences

Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.

Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.

Molecular Data

pGlu

Position 1

Glutamic Acid

Position 2

Leucine

Position 3

Position 4

Arginine

Position 5

Alanine

Position 6

Position 7

Asparagine

Position 8

Serine

Position 9

Position 10

Research Indications

23% increase in corneal nerve fiber area with sustained pain improvement.

Nerve regeneration and metabolic improvements in Type 2 diabetes patients.

Crosses blood-brain barrier for stroke and TBI neuroprotection.

Improves epithelialization and angiogenesis via VEGF upregulation.

Reduces infarct size in myocardial infarction models.

Maintains cardiac function in aging models.

Reduces TNF-α, IL-6, and IL-12 production.

Reduces colitis severity in animal models.

Improves graft survival and reduces rejection.

Dosing Protocols

Primary clinical administration route with proven efficacy.

Neuropathy Treatment

4 mg daily

Once daily

SubQ

Tissue Protection

1-8 mg daily

Acute Intervention

2 mg

3x weekly

IV

Reconstitution Instructions

Ara 290 lyophilized powder (4 mg vial)

Sterile water for injection

Sterile syringes and needles

Alcohol swabs

Light protection

1 Allow vial to reach room temperature (15-20 minutes)

2 Clean vial top with alcohol swab

3 Slowly inject 1 mL sterile water

4 Gently swirl to dissolve (no vigorous shaking)

5 Slight cloudiness is normal

6 Use immediately or refrigerate up to 24 hours

7 Protect from light

8 Rotate injection sites

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Excellent safety profile in clinical trials with no serious drug-related adverse events

Stop Signs - Discontinue if:

Severe injection site reactions

Unexpected blood count changes

Allergic reaction signs

Worsening of underlying condition

New neurological symptoms

Any serious adverse events

Contraindications

Recent anti-TNF therapy (within 6 months)

EPO use (within 2 months)

Pregnancy

BMI > 34 kg/m²

Quality Checklist

Good Signs

Pharmaceutical grade manufacturing with GMP conditions

Proper peptide sequence verification - correct 11-amino acid sequence with N-terminal pyroglutamate

Sterile lyophilized powder with proper freeze-drying

Clinical batch documentation - Purity >95%, endotoxin <1 EU/mg, sterility verified

Warning Signs

Light-sensitive formulation - requires protection during storage and use

Bad Signs

Cloudy or discolored solution indicates degradation; should be clear to slightly cloudy

Frequently Asked Questions

How does Ara-290 differ from erythropoietin (EPO) for neuroprotection?

Ara-290 is an engineered 11-amino acid peptide derived from EPO structure that activates the Innate Repair Receptor (IRR) without triggering erythropoiesis. It provides tissue protection and nerve regeneration like EPO but without red blood cell stimulation, polycythemia risk, or thrombotic complications.

What's the timeline for nerve regeneration with Ara-290 in diabetic neuropathy?

Phase 2 trials showed 23% increase in corneal nerve fiber area at 4mg daily for 28 days, with sustained pain improvements. Nerve fiber regeneration markers appeared within weeks 2-4, with peak therapeutic effects and maximum improvements by week 4-6. Benefits persist via molecular switch effects through month 2-6.

Can I combine Ara-290 with other neuroprotective peptides like BPC-157?

Yes. BPC-157 and Ara-290 target complementary tissue repair pathways with no known direct interactions. TB-500 is also synergistic. These combinations likely enhance recovery from injury, though clinical data on simultaneous use doesn't exist.

Why must I avoid anti-TNF biologics or recent EPO use before starting Ara-290?

Anti-TNF therapy requires 6-month washout before Ara-290 due to immune interaction risks. EPO use requires 2-month washout because both target related receptor pathways. These washout periods prevent unpredictable receptor interference and potential adverse immune effects from concurrent use.

References

Phase 2b trial, 64 subjects with sarcoid neuropathy, 1-8mg SC daily for 28 days. Cibinetide significantly increased corneal and skin small nerve fiber abundance, consistent with disease-modifying effect. 23% increase in corneal nerve fiber area at 4mg dose.

Phase 2 trial, 4mg SC daily for 28 days in T2DM patients. Improvement in HbA1c and lipid profiles sustained 4 weeks post-dosing. Neuropathic symptoms significantly improved. Corneal nerve fiber density increased.

9 patients, 4mg SC daily for 12 weeks. No serious adverse events. Improvement in NEI VFQ-25 composite quality of life scores. Some participants showed improvements in CRT, tear production, diabetic control, and albuminuria.

Engineered helix B surface peptide (pHBSP/ARA-290) from EPO structure. Increased reactive oxygen species threshold for mitochondrial permeability transition by 40%. Reduced ischemic myocardial infarct size equivalent to EPO without erythropoietic effects.

pHBSP reduced contusion volume from 20.8mm3 (control) to 5.9mm3. Improved cerebral blood flow recovery and beam-walking performance. Neuroprotective effects similar to EPO without thrombotic risk.

Related Peptides

Complementary tissue repair pathways may enhance wound healing.

Combined mechanisms enhance recovery from injury.

No known interactions; different mechanisms for tissue protection.

No adverse interactions in clinical trials with GLP-1 agonists.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.